Natera (NASDAQ:NTRA) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Natera (NASDAQ:NTRA – Get Rating) in a research note released on Thursday. The firm issued a sell rating on the medical research company’s stock.

NTRA has been the subject of a number of other research reports. Credit Suisse Group upped their price target on Natera from $55.00 to $65.00 and gave the stock an outperform rating in a report on Wednesday, March 1st. Piper Sandler upped their target price on Natera from $70.00 to $80.00 in a research report on Friday, February 17th. Raymond James upped their target price on Natera from $58.00 to $68.00 and gave the company an outperform rating in a research report on Friday, March 3rd. Stephens cut their target price on Natera to $67.00 in a research report on Wednesday, November 16th. Finally, Morgan Stanley upped their target price on Natera from $70.00 to $72.00 and gave the company an overweight rating in a research report on Thursday, March 2nd. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus target price of $79.27.

Natera Stock Down 2.8 %

NASDAQ NTRA opened at $56.63 on Thursday. The stock has a market cap of $6.42 billion, a PE ratio of -10.17 and a beta of 1.20. Natera has a fifty-two week low of $27.35 and a fifty-two week high of $59.75. The business has a 50 day moving average price of $47.11 and a two-hundred day moving average price of $44.26. The company has a quick ratio of 3.79, a current ratio of 3.90 and a debt-to-equity ratio of 0.40.

Natera (NASDAQ:NTRA – Get Rating) last released its quarterly earnings results on Tuesday, February 28th. The medical research company reported ($1.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.40) by $0.03. The firm had revenue of $217.30 million during the quarter, compared to analysts’ expectations of $215.50 million. Natera had a negative return on equity of 106.67% and a negative net margin of 66.79%. Natera’s quarterly revenue was up 25.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.48) EPS. As a group, sell-side analysts predict that Natera will post -4.22 EPS for the current fiscal year.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 1,660 shares of the company’s stock in a transaction that occurred on Friday, December 23rd. The stock was sold at an average price of $42.30, for a total transaction of $70,218.00. Following the sale, the chief executive officer now directly owns 82,632 shares of the company’s stock, valued at approximately $3,495,333.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CEO Steven Leonard Chapman sold 1,660 shares of the company’s stock in a transaction that occurred on Friday, December 23rd. The stock was sold at an average price of $42.30, for a total transaction of $70,218.00. Following the sale, the chief executive officer now directly owns 82,632 shares of the company’s stock, valued at approximately $3,495,333.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Daniel Rabinowitz sold 2,387 shares of the company’s stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $41.56, for a total value of $99,203.72. Following the sale, the insider now directly owns 148,853 shares in the company, valued at $6,186,330.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 187,145 shares of company stock valued at $8,648,357. Corporate insiders own 10.27% of the company’s stock.

Institutional Investors Weigh In On Natera

Several large investors have recently added to or reduced their stakes in the stock. Signaturefd LLC increased its position in Natera by 12.9% in the third quarter. Signaturefd LLC now owns 2,094 shares of the medical research company’s stock worth $92,000 after buying an additional 240 shares during the period. Arizona State Retirement System increased its position in Natera by 1.2% in the third quarter. Arizona State Retirement System now owns 24,864 shares of the medical research company’s stock worth $1,090,000 after buying an additional 285 shares during the period. Amalgamated Bank increased its position in Natera by 1.7% in the third quarter. Amalgamated Bank now owns 19,301 shares of the medical research company’s stock worth $846,000 after buying an additional 322 shares during the period. Profund Advisors LLC increased its position in Natera by 3.3% in the third quarter. Profund Advisors LLC now owns 10,571 shares of the medical research company’s stock worth $463,000 after buying an additional 337 shares during the period. Finally, Public Employees Retirement System of Ohio increased its position in Natera by 0.8% in the third quarter. Public Employees Retirement System of Ohio now owns 43,299 shares of the medical research company’s stock worth $1,897,000 after buying an additional 341 shares during the period. 93.81% of the stock is owned by institutional investors and hedge funds.

About Natera

(Get Rating)

Natera, Inc is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).